Pancreatic ductal adenocarcinoma is one of the most aggressive and lethal cancers.Surgical resection is the only curable treatment option,but it is available for only a small fraction of patients at the time of diagno...Pancreatic ductal adenocarcinoma is one of the most aggressive and lethal cancers.Surgical resection is the only curable treatment option,but it is available for only a small fraction of patients at the time of diagnosis.With current therapeutic regimens,the average 5-year survival rate is less than 10%in pancreatic cancer patients.Immunotherapy has emerged as one of the most promising treatment options for multiple solid tumors of advanced stage.However,its clinical efficacy is suboptimal in most clinical trials on pancreatic cancer.Current studies have suggested that the tumor microenvironment is likely the underlying barrier affecting immunotherapy drug efficacy in pancreatic cancer.In this review,we discuss the role of the tumor microenvironment in pancreatic cancer and the latest advances in immunotherapy on pancreatic cancer.展开更多
文摘Pancreatic ductal adenocarcinoma is one of the most aggressive and lethal cancers.Surgical resection is the only curable treatment option,but it is available for only a small fraction of patients at the time of diagnosis.With current therapeutic regimens,the average 5-year survival rate is less than 10%in pancreatic cancer patients.Immunotherapy has emerged as one of the most promising treatment options for multiple solid tumors of advanced stage.However,its clinical efficacy is suboptimal in most clinical trials on pancreatic cancer.Current studies have suggested that the tumor microenvironment is likely the underlying barrier affecting immunotherapy drug efficacy in pancreatic cancer.In this review,we discuss the role of the tumor microenvironment in pancreatic cancer and the latest advances in immunotherapy on pancreatic cancer.
基金supported by the National Cancer Institute/the National Institute of Health(1R01CA197976,1R01CA201500)Vincent Memorial Hospital Foundation+6 种基金the Vincent Center for Reproductive Biologythe Olson Center for Women’s HealthUniversity of Nebraska Medical Center Graduate Studies Fellowshipthe Fred&Pamela Buffett Cancer Center(LB595)Colleen’s Dream FoundationMarsha Rivkin Center for Ovarian Cancer Research(the Barbara Learned Bridge Funding Award)the Co BRE grant from the Nebraska Center for Cellular Signaling/the National Institute of General Medical Science/the National Institute of Health(5P30GM106397)。
